CNS delivery of l-dopa by a new hybrid glutathione–methionine peptidomimetic prodrug
Parkinson’s disease (PD) is a neurodegenerative disorder associated primarily with loss of dopamine (DA) neurons in the nigrostriatal system. With the aim of increasing the bioavailability of l-dopa (LD) after oral administration and of overcoming the pro-oxidant effect associated with LD therapy, we designed a peptidomimetic LD prodrug (1) able to release the active agent by enzyme catalyzed hydrolysis. The physicochemical properties, as well as the chemical and enzymatic stabilities of the new compound, were evaluated in order to check both its stability in aqueous medium and its sensitivity towards enzymatic cleavage, providing the parent LD drug, in rat and human plasma. The radical scavenging activities of prodrug 1 was tested by using both the DPPH–HPLC and the DMSO competition methods. The results indicate that the replacement of cysteine GSH portion by methionine confers resistance to oxidative degradation in gastric fluid. Prodrug 1 demonstrated to induce sustained delivery of DA in rat striatal tissue with respect to equimolar LD dosages. These results are of significance for prospective therapeutic application of prodrug 1 in pathological events associated with free radical damage and decreasing DA concentration in the brain.
Keywordsl-Dopa Glutathione Methionine Parkinson’s disease
Financial support from Ministero dell’ Istruzione, dell’Università e della Ricerca (MIUR) is gratefully acknowledged.
Conflict of interest
The authors declare that they have no conflict of interest.
- Angelini G, Cusan C, De Maria P, Fontana A, Maggini M, Pierini M, Prato M, Schergna S, Villani C (2005) The associative properties of some amphiphilic fullerene derivatives. Eur J Org Chem 9:1884–1891Google Scholar
- Di Stefano A, Sozio P, Iannitelli A, Cerasa LS, Fontana A, Di Biase G, D’Amico G, Di Giulio M, Carentiero C, Grumetto L, Barbato F (2008) Characterization of alkanoyl-10-O-minocyclines in micellar dispersions as potential agents for treatment of human neurodegenerative disorders. Eur J Pharm Sci 34:118–128PubMedCrossRefGoogle Scholar
- Everts M, Schraa AJ, de Leij LFMH, Meijer DKF, Molema G (2001) Brain-specific drug targeting strategies. In: Molema G, Meijer DKF (eds) Drug targeting-organ specific strategies. Wiley-VCH, Weinheim, pp 23–52Google Scholar
- Garzon-Aburbeh A, Poupaert JH, Claesen M, Dumont PA (1986) Lymphotropic prodrug of l-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1, 3-dihexadecanoyl-2-[(S)-2-amino-3-(3, 4-dihydroxyphenyl)prop anoyl] propane-1, 2, 3-triol. J Med Chem 29:687–691PubMedCrossRefGoogle Scholar
- Giorgioni G, Claudi F, Ruggieri S, Ricciutelli M, Palmieri GF, Di Stefano A, Sozio P, Cerasa LS, Chiavaroli A, Ferrante C, Orlando G, Glennon RA (2010) Design, synthesis and preliminary pharmacological evaluation of new imidazolinones as l-DOPA prodrugs. Bioorg Med Chem 18:1834–1843PubMedCrossRefGoogle Scholar
- Marrel C, Boss G, Van De Waterbeemd H, Testa B, Cooper D, Jenner P, Marsden CD (1985) l-Dopa esters as potential prodrugs. Eur J Med Chem-Chim Ther 20:459–465Google Scholar
- Melagraki G, Afantitis A, Igglessi-Markopoulou O, Detsi A, Koufaki M, Kontogiorgis C, Hadjipavlou-Litina DJ (2009) Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts. Eur J Med Chem 44:3020–3026PubMedCrossRefGoogle Scholar
- Pinnen F, Cacciatore I, Cornacchia C, Sozio P, Cerasa LS, Iannitelli A, Nasuti C, Cantalamessa F, Sekar D, Gabbianelli R, Falcioni ML, Di Stefano A (2009) Codrugs linking l-dopa and sulphur-containing antioxidants: new pharmacological tools against Parkinson’s disease. J Med Chem 52:559–564PubMedCrossRefGoogle Scholar
- Sozio P, Iannitelli A, Cerasa LS, Cacciatore I, Cornacchia C, Giorgioni G, Ricciutelli M, Nasuti C, Cantalamessa F, Stefano Di (2008) A new l-dopa codrugs as potential antiparkinson agents. Arch Pharm 341:412–417Google Scholar
- Yalkowsky SH, Morozowich W (1980) A physical chemical basis for the design of orally active prodrugs. In: Ariens EJ (ed) Drug design, vol 9. Academic Press, New York, pp 121–135Google Scholar